Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-JK-PSMA-07
- Development stage
- Unknown
- Lead developer
- circumSPECT
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-JK-PSMA-07 (also known as 18F-JK-PSMA-7 or 2-methoxy-18F-DCFPyL) is a novel fluorine-18 labeled small-molecule radiopharmaceutical designed for positron emission tomography (PET) imaging of prostate cancer. It is a urea-based ligand that specifically binds to prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein overexpressed in prostate cancer cells and metastatic lesions. Developed jointly by Forschungszentrum Jülich and the University Hospital of Cologne, the tracer features a methoxy group on the fluoropyridine ring of the DCFPyL scaffold, which enhances its target-to-background ratio and cellular uptake. Licensed globally to circumSPECT and co-developed with ITEL Telecomunicazioni (Itelpharma), 18F-JK-PSMA-07 has advanced to Phase 3 clinical trials for the detection and localization of recurrent prostate cancer in patients with biochemical recurrence.
- Other names
- (((S)-1-carboxy-5-(6-[18F]fluoro-2-methoxynicotinamido)pentyl)carbamoyl)-l-glutamic acid2-MeO-18F-DCFPyL2-MeO-[18F]DCFPyL2-methoxy-18F-DCFPyL[18F]JK-PSMA-07[18F]JK-PSMA-7
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 18F-JK-PSMA-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-JK-PSMA-07.